OTCM
RGEDF
Oct 21, Last price
39.43
1D
-1.01%
1Q
6.59%
Name
Richter Gedeon Vegyeszeti Gyar Nyrt
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
Key people
Gyorgy Bagdy
Member of the Board of Directors · since 2019
Ilona Hardy
Non-Executive Independent Member of the Board of Directors
Anett Pandurics
Non-Executive Independent Member of the Board of Directors
Balint Szecsenyi
Non-Executive Independent Member of the Board of Directors · since 2018
Jonathan Robert Bedros
Independent Member of the Supervisory Board · since 2012
Independent Member of the Supervisory Board · since 2018
IPO date
Nov 09, 1994
Employees
12,167
Domiciled in
HU
Incorporated in
HU
Headquarters & legal address
GYOMROI UT 19-21
BUDAPEST, BU 1103
HU
BUDAPEST, BU 1103
HU
Trading name
RICHTER GEDEON NYRT.
Previous name
RICHTER GEDEON VEGYÉSZETI GYÁR RT.
Valuation
Title HUF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||